

Date of preparation: 13 January 2026

Issuer's abbreviated name: SYNEKTIK SA

Current report: 4/2026 ESPI

Subject: Information on the conclusion of a significant agreement on the sale of a robotic system

Legal basis: Art. 17 sec. 1 MAR – inside information

Body of the report:

Time of publication: 8:30 a.m.

The Management Board of Synektik SA ("Company") reports that the Company has learned of the conclusion of significant agreement by the subsidiary doing business as SYNEKTIK Czech Republic, s.r.o. with its registered office in Prague, Czech Republic with Městská nemocnice Ostrava, příspěvková organizace with its registered office at Nemocniční 898/20a, 728 80 Ostrava – Moravská Ostrava, Czech Republic (Hospital).

The agreement pertains to the sale, delivery, installation and commissioning of the da Vinci minimally invasive surgery robotic system for the Hospital with personnel training and warranty maintenance care.

The agreement was concluded as a result of a proceeding conducted under Czech public procurement law and their total net value is USD 3,044,856.01.

The robotic system will be delivered to the Hospital within 180 days of the Hospital submitting its request for delivery of the system. The warranty period for system delivery is 24 months from signing the final acceptance report. The other clauses of the agreement do not deviate from the standards generally used in agreements of this type.

The signing of this agreement has been deemed to be significant by the Management Board of Synektik SA since its net value exceeds 5% of the equity of the Synektik Group disclosed in the last periodic report, meaning that it surpasses the level prescribed internally in the Company in its individual reporting



standards. The proceeds generated by executing the project will affect the sales results in the 2025 financial year lasting from 1 October 2025 to 30 September 2026.

Persons representing the Issuer:

Cezary Kozanecki – President of the Management Board